AURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Aura Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$6.29+0.19 (+3.11%)

Close on Oct 19, 2026

Market cap: $596.69M
P/E (TTM): –
Dividend yield: –

Aura Biosciences, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Research & Development	90	73	65	42	25	18
General & Administrative	22	23	20	18	10	4.16
Operating Income	-113	-96	-85	-60	-35	-22
Other Non-Operating Income	6.71	9.31	8.72	1.53	0.00	–
Asset Impairment Charges	0	0	0	0	–	–
Gain (Loss) on Investments	–	–	–	-0.01	–	–
Gain (Loss) on Sale of Assets	–	0	0.21	-0.32	0.00	–
Pretax Income	-106	-87	-76	-59	–	–
Income Tax Expense	0.11	0.11	0.14	0	0	0
Net Income incl. Noncontrolling Interests	-106	-87	-76	-59	-35	-22
Net Income	-106	-87	-76	-59	-35	-22
Preferred Dividends	–	–	–	–	11	–
EPS (Basic)(per share)	-1.76	-1.75	-1.93	-1.96	-8.95	-82.06
EPS (Diluted)(per share)	-1.76	-1.75	-1.93	-1.96	-8.95	-82.06
Shares Outstanding (Basic, Weighted)(shares)	60	50	40	30	5.16	0.37
Shares Outstanding (Diluted, Weighted)(shares)	60	50	40	30	5.16	0.37

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -73.5%

Financial strength

Current ratio: 16.82
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 346.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.89
Dividend yield: –